In an adult with acute bacterial rhinosinusitis who has failed azithromycin and is currently receiving high‑dose amoxicillin‑clavulanate, can cefuroxime be added to the regimen?

Do Not Add Cefuroxime to High-Dose Amoxicillin-Clavulanate

You should not add cefuroxime to the current high-dose amoxicillin-clavulanate regimen. Instead, you need to switch to an alternative antibiotic, as this represents treatment failure of first-line therapy.

Why Adding Antibiotics is Not Recommended

The patient has already failed azithromycin (which was inappropriate initial therapy) and is now on high-dose amoxicillin-clavulanate. Adding cefuroxime creates polypharmacy without addressing the underlying issue: resistant organisms or inadequate treatment duration.

• No guideline recommends combination therapy for uncomplicated acute bacterial rhinosinusitis (ABRS) 1
• Combining beta-lactams (amoxicillin-clavulanate + cefuroxime) provides overlapping coverage without meaningful benefit
• This approach increases adverse effects (particularly diarrhea) without improving outcomes

The Correct Approach: Switch, Don't Add

Step 1: Assess Treatment Duration

• Has the patient been on high-dose amoxicillin-clavulanate for at least 5-7 days? 1
• If less than 5-7 days, continue current therapy and reassess

Step 2: If True Treatment Failure (After 5-7 Days)

Switch to a respiratory fluoroquinolone (levofloxacin or moxifloxacin) as second-line therapy 1

Alternative second-line options include:

• Doxycycline
• Combination therapy: clindamycin PLUS a third-generation cephalosporin (cefixime or cefpodoxime)

Step 3: Consider Complications

If symptoms are severe or worsening, evaluate for:

• Orbital cellulitis
• Meningitis
• Abscess formation
• These require imaging (CT) and possible ENT referral 2

Why Cefuroxime Alone Would Be Inferior

While cefuroxime has been studied as monotherapy for ABRS and shows comparable efficacy to amoxicillin-clavulanate 3, 4, 5, it is:

• Not superior to amoxicillin-clavulanate
• Less effective against beta-lactamase producing organisms than high-dose amoxicillin-clavulanate
• Not recommended as second-line therapy after amoxicillin-clavulanate failure 1

The research showing cefuroxime efficacy 3, 4, 5 was in treatment-naive patients, not in those who failed first-line therapy.

Critical Pitfall to Avoid

Azithromycin should never have been first-line therapy for ABRS. The 2012 IDSA guidelines explicitly recommend amoxicillin-clavulanate as first-line 1, and the 2025 AAO-HNS update reinforces this 6. Macrolides like azithromycin have high resistance rates among Streptococcus pneumoniae and Haemophilus influenzae, the primary ABRS pathogens.

Practical Algorithm

1. Confirm diagnosis: Symptoms >7 days OR worsening after initial improvement OR severe symptoms (fever >102°F, purulent discharge, facial pain) for ≥3 days 2

2. Verify adequate treatment: High-dose amoxicillin-clavulanate (2g BID or 875mg TID) for 5-7 days 1, 7

3. If persistent after 5-7 days: Switch to levofloxacin 750mg daily or moxifloxacin 400mg daily for 5-7 days 1

4. Add adjunctive therapy: Intranasal corticosteroids and saline irrigation improve symptom resolution 1

The bottom line: Switching antibiotics after documented treatment failure is evidence-based; adding antibiotics is not.